BCL2L1 and cancer: Most of the developed inhibitors belonged to the event‐driven pharmacology‐based approaches (PROTAC and SNIPER‐based design), with some examples of prodrug approaches (phosphate‐prodrugs, dendrimers, and glycosylation).[29] Unlike the differences in the strategies, the pharmacodynamic objective remains the same: to reduce the platelet toxicity of Bcl‐xL inhibitors by incorporating newer elements that can take advantage of those enzymes or proteins specifically expressed in cancer and senescent cells than platelets.